摘要
肿瘤患者易并发血栓栓塞,且已成为其重要死因。相较于传统低分子肝素疗法,Xa因子抑制剂阿哌沙班在临床抗凝治疗中表现更优。现有研究表明,该药用于肿瘤相关静脉血栓栓塞症的预防和治疗颇具前景,但仍存在潜在风险。本文综合评估阿哌沙班在防治肿瘤相关静脉血栓栓塞症的疗效与安全性,权衡其临床应用的利弊,为肿瘤患者的抗凝决策提供参考依据。
Thromboembolism is easy to occur in cancer patients and has become an important cause of death.Compared with traditional low molecular weight heparin therapy,the Factor Xa inhibitor apixaban has better performance in clinical anticoagulant therapy.Existing studies have shown that the drug is promising for the prevention and treatment of cancer-associated venous thromboembolism,but there are still potential risks.This article comprehensively evaluats the efficacy and safety of apixaban in the prevention and treatment of cancer-associated thromboembolism,weighs the advantages and disadvantages of its clinical application,and provides a reference for anticoagulant decision-making in cancer patients.
作者
武珊珊
李敏妍
张文杰
WU Shanshan;LI Minyan;ZHANG Wenjie(Department of Pharmacy,Guangzhou Panyu District Maternal and Child Health Hospital,Guangzhou,Guangdong 511400,China;不详)
出处
《中国处方药》
2026年第2期113-116,共4页
Journal of China Prescription Drug
基金
广州市番禺区科技计划项目(2024-Z04-067)。
